CLX Investment Company, Inc. (OTCBB: CLXN) today announced that applications for CE marks have been filed on behalf of portfolio investment company Zonda Incorporated's over-the-counter diagnostic tests for gonorrhea, yeast (Candida albicans) and group A strep. CE marks signify that products comply with the relevant health, safety, and environmental protection requirements and can therefore be legally placed on the market in Europe.
